ALK and non-small cell lung carcinoma: The assessment of the mutational status of predictive biomarkers, such as Epidermal Growth Factor Receptor (EGFR), Anaplastic Lymphoma Kinase (ALK), ROS Proto-Oncogene 1 Receptor Tyrosine Kinase (ROS1), and V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF), plays a crucial role in the identification of the most suitable therapeutic strategy for NSCLC patients in the current clinical practice.